ENAapplication/xmlftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR247/020/SRR24742220/SRR24742220_1.fastq.gzftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR247/023/SRR24742223/SRR24742223_1.fastq.gzftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR247/023/SRR24742223/SRR24742223_2.fastq.gzftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR247/022/SRR24742222/SRR24742222_1.fastq.gzftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR247/020/SRR24742220/SRR24742220_2.fastq.gzftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR247/021/SRR24742221/SRR24742221_2.fastq.gzftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR247/021/SRR24742221/SRR24742221_1.fastq.gzftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR247/022/SRR24742222/SRR24742222_2.fastq.gzprimaryOK200GenomicsDepartment of Veterans Affairshttps://www.ebi.ac.uk/ena/browser/view/PRJNA976292Homo sapiensxref:PubMed:37421947To investigate the effect of HDAC inhibition, we treated MKL1 cells with 10µM of domatinostat or vehicle control (DMSO) for 24h, and carried out bulk RNA-seq We then performed gene expression profiling analysis using data obtained from RNA-seq of vehicle control (DMSO treated) and domatinostat treated samples (in duplicates) Overall design: Comparative gene expression profiling analysis of RNA-seq data for untreated and treated MKL1 cells.ENA4SC-202, treatment, Therapy, MRTF-A, MELODY, Therapeutic, Mrtf-a, Mrtf-A, BSAC, Bsac, disease management, FLMKL1, Therapies, Treatment, AMKL, Cell., MAL, Mal, MKL1met, Treatments4SC-202, treatment, Therapy, MRTF-A, MELODY, Therapeutic, Mrtf-a, Mrtf-A, BSAC, Bsac, disease management, FLMKL1, Therapies, Treatment, AMKL, Cell., MAL, Mal, MKL1met, TreatmentsfalseEffect of Domatinostat treatment on MKL1 cellsEffect of Domatinostat treatment on MKL1 cells2025-09-242023-06-03PRJNA976292GSE233454960637421947